BIONTECH SE (BNTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
Research Workspace
Put BNTX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisModerate volatility — typically moves about 1% a day.
View RiskNot enough reads yet
BioNTech's late-stage cancer pipeline has to keep compounding to justify the price. The company beat Q3 estimates and raised its 2026 revenue guidance. This result supports the argument that growth is accelerating. We cannot anchor a clean multiple for BNTX right now. Analysts target a value that is low-confidence. The price is roughly in line with the growth we forecast. A missed trial endpoint could break the thesis. Peer multiples imply a price about 31% above where it trades. Our read remains intact. This read is provisional.
End-of-day figures as of 2026-11-05. EPS is implied from price ÷ P/E. Not investment advice.
Trailing returns as of 2026-11-05. BNTX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering BNTX (as of Nov 2026).
Based on 4 Wall Street analysts offering 12-month price targets for BNTX in the last 4 months.
Current $85.86
The last 12 months of price, then the range of analyst 12-month targets from today’s $85.86.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare BNTX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BNTX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put BNTX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Raised 2026 guidance signals strong future growth confidence.

Earnings beat confirms operational execution and financial health.

Global Phase 2 data support pumitamig’s potential in advanced NSCLC after prior treatment.

Missed trial endpoint undermines product viability and future revenue.

Increased visibility of late-stage cancer drugs supports growth potential.

Closure of sites indicates operational setbacks and strategic misalignment.

Positive lung cancer data supports product development and market potential.

Positive trial data supports product development and market potential.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.